Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP950750.RA-DQWzr8GRCjzvTr8hxLK1XhsLnOYCSpsIJGvBZ66TQ0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP950750.RA-DQWzr8GRCjzvTr8hxLK1XhsLnOYCSpsIJGvBZ66TQ0130_assertion type Assertion NP950750.RA-DQWzr8GRCjzvTr8hxLK1XhsLnOYCSpsIJGvBZ66TQ0130_head.
- NP950750.RA-DQWzr8GRCjzvTr8hxLK1XhsLnOYCSpsIJGvBZ66TQ0130_assertion description "[First, immune-based therapies are being developed (eg, elotuzumab monoclonal antibody [MoAb]; CD138DM immunotoxin; MM cell-dendritic cell vaccines; CD138, CS-1, and XBP-1 peptide vaccines; anti-17 MoAb; and other treatments to overcome causes of immune dysfunction).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP950750.RA-DQWzr8GRCjzvTr8hxLK1XhsLnOYCSpsIJGvBZ66TQ0130_provenance.
- NP950750.RA-DQWzr8GRCjzvTr8hxLK1XhsLnOYCSpsIJGvBZ66TQ0130_assertion evidence source_evidence_literature NP950750.RA-DQWzr8GRCjzvTr8hxLK1XhsLnOYCSpsIJGvBZ66TQ0130_provenance.
- NP950750.RA-DQWzr8GRCjzvTr8hxLK1XhsLnOYCSpsIJGvBZ66TQ0130_assertion SIO_000772 22215754 NP950750.RA-DQWzr8GRCjzvTr8hxLK1XhsLnOYCSpsIJGvBZ66TQ0130_provenance.
- NP950750.RA-DQWzr8GRCjzvTr8hxLK1XhsLnOYCSpsIJGvBZ66TQ0130_assertion wasDerivedFrom befree-2016 NP950750.RA-DQWzr8GRCjzvTr8hxLK1XhsLnOYCSpsIJGvBZ66TQ0130_provenance.
- NP950750.RA-DQWzr8GRCjzvTr8hxLK1XhsLnOYCSpsIJGvBZ66TQ0130_assertion wasGeneratedBy ECO_0000203 NP950750.RA-DQWzr8GRCjzvTr8hxLK1XhsLnOYCSpsIJGvBZ66TQ0130_provenance.